Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is advancing a two-pronged approach to neurological health, targeting both multiple sclerosis (MS) and alcohol misuse disorders. The company is developing Lucid-MS, an investigational therapy designed to protect and potentially restore the myelin sheath in MS patients, and unbuzzd, a proprietary dietary supplement aimed at reducing acute intoxication and hangover effects.
Lucid-MS represents a novel mechanism of action, targeting the enzyme PAD2, which is associated with myelin degradation. Unlike conventional MS therapies that primarily modulate the immune system, Lucid-MS aims to directly address the underlying myelin damage. The company has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for a Phase 2 trial. To support the development of Lucid-MS, Quantum BioPharma is collaborating with Massachusetts General Hospital on imaging techniques to assess myelin repair.
In parallel, Quantum BioPharma's unbuzzd supplement is designed to support alcohol metabolism and reduce the effects of acute intoxication and hangovers. The company cites results from a randomized, placebo-controlled clinical trial that demonstrated its efficacy. unbuzzd is being commercialized through Unbuzzd Wellness Inc. (UWI), a company led by industry veterans, in which Quantum BioPharma retains a 19.84% ownership stake as of March 31, 2026. The agreement includes royalty payments of 7% of sales from unbuzzd until payments total $250 million, after which the royalty drops to 3% in perpetuity. Quantum BioPharma retains 100% of the rights to develop similar products or alternative formulations for pharmaceutical and medical uses.
The strategic importance of this dual approach lies in its potential to address two significant unmet medical needs. MS is a chronic, debilitating disease affecting millions worldwide, and current treatments often have limited efficacy in reversing neurological damage. By targeting myelin repair directly, Lucid-MS could offer a disease-modifying therapy that goes beyond symptom management. The collaboration with Massachusetts General Hospital underscores the scientific rigor behind this effort.
Meanwhile, unbuzzd addresses the widespread issue of alcohol misuse, which has substantial health and societal costs. The supplement's ability to mitigate hangover symptoms and support alcohol metabolism could appeal to a broad consumer market, providing a revenue stream that supports the company's research and development activities. The royalty structure ensures long-term financial benefits for Quantum BioPharma as unbuzzd gains market traction.
For investors, the progress of Lucid-MS through regulatory milestones and the commercial potential of unbuzzd represent key value drivers. The company's focus on innovative therapies for neurodegenerative and metabolic disorders positions it in a high-growth sector. As Quantum BioPharma continues to advance its pipeline, the outcomes of the Phase 2 trial and the market performance of unbuzzd will be critical factors to monitor.
For more information about Quantum BioPharma, visit the company's newsroom at https://ibn.fm/QNTM. To view the full article, visit https://ibn.fm/Rl89U.
